The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,012.00
Ask: 12,016.00
Change: -268.00 (-2.18%)
Spread: 4.00 (0.033%)
Open: 12,226.00
High: 12,266.00
Low: 11,988.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU expects to vaccinate majority by end-June - Bloomberg

Tue, 06th Apr 2021 10:33

(Adds details)

April 6 (Reuters) - Most European Union states will have
enough COVID-19 vaccines to immunize the majority of their
people by the end of June, Bloomberg News reported on Tuesday,
citing an internal memo.

Germany, France, Italy, Spain and the Netherlands will be in
a position to fully inoculate more than 55% of their populations
by June end, the report https://www.bloomberg.com/news/articles/2021-04-06/eu-will-near-virus-immunity-by-end-june-internal-memo-shows?sref=SCAzRb9t
added, citing projections in the memo by the EU executive, the
European Commission.

The numbers confirm public estimates of vaccines the
27-nation bloc expects to receive in the second quarter.

The Commission has repeatedly said the EU, with a population
of nearly 450 million, is to receive about 360 million doses by
the end of June in addition to about 100 million already
shipped.

That would be sufficient to meet its target of vaccinating
at least 70% of the bloc's adult population by the summer.

The bloc expects to receive in the April-June period 55
million doses of the single-dose vaccine developed by Johnson &
Johnson, and another 300 million of two-dose shots from
BioNTech-Pfizer , AstraZeneca and
Moderna.

It is however unclear whether all expected doses will be
delivered in line with timetables. The EU received about half of
the expected doses in the first quarter because AstraZeneca made
major cuts in its supplies to the EU then.

The new estimates already factor in a further major cut in
AstraZeneca supplies in the second quarter.

The EU has coordinated the purchase of vaccines with EU
governments but has no power on vaccination plans, which are run
by EU states.

Roll-outs depend on supplies but also on vaccination
programmes, which have often been hampered in EU states because
of safety and effectiveness concerns over the AstraZeneca
vaccine.

The vaccine roll-out picked up in the bloc at the end of
March after a slow start.
(Reporting by Aakriti Bhalla in Bengaluru; additional reporting
by Francesco Guarascio in Brussels; Editing by Andrew Cawthorne
and Giles Elgood)

More News
Today 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
21 May 2024 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
21 May 2024 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
21 May 2024 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.